The first of the two recent studies reporting risks with testosterone prescriptions, published in the Journal of the American Medical Association by Vigen et al (1), was a retrospective analysis of a dataset of 8709 men in the VA health system who had undergone coronary angiography. Among men with testosterone concentrations less than 300ng/dl, the authors reported an increased rate of heart attacks, strokes, and deaths in men who received a testosterone prescription compared with men who did not.

Pharmacologic treatment of premature ejaculation represents a new approach to the treatment of PE and a radical departure from the psychosexual model of treatment. There have been many papers discussing this topic. I chose to write a clinical paper, in the form of Questions and Answers, which is an innovative way of writing an article (with several citations) to help clinicians in the management of premature ejaculation.